NEOTRACT, INC.

Teleflex Interventional Urology, operating under the UroLift brand, manufactures and markets the UroLift™ System, a minimally invasive medical device for the treatment of benign prostatic hyperplasia (BPH) in men. The UroLift System uses tiny permanent implants placed via cystoscopy to mechanically lift and hold obstructed prostate tissue away from the urethra, restoring normal urine flow without cutting, heating, or removing prostate tissue. FDA-cleared in 2013, the system is performed as an outpatient procedure under local anesthesia with typical treatment time of 1–2 hours and rapid symptom relief within days. Clinical data demonstrate superior outcomes compared to medication therapy, with no instances of new sustained erectile or ejaculatory dysfunction—a key differentiator from traditional surgical approaches. The device is covered by Medicare and major commercial insurance plans when medical criteria are met. Over 500,000 patients worldwide have been treated with UroLift. The company also provides patient education, physician training, reimbursement support, and a physician finder service. Headquartered in Pleasanton, California, Teleflex Interventional Urology is part of Teleflex Incorporated, a global medical device manufacturer.